SFRP4 Is a Potential Biomarker for the Prognosis and Immunotherapy for Gastric Cancer

Table 3

Association of SFRP4 expression with clinicopathological characteristics of patients with gastric cancer (n = 137).

Variables	Expression		Total	High rate	χ^2	value^b
	High	Low
Age (year)
>60	52	21	73	71.23%	0.100	0.752
≤60	44	20	64	68.75%
Sex
Female	30	10	40	75.00%	0.654	0.419
Male	66	31	97	68.04%
Smoking
Yes	33	17	50	66.00%	0.623	0.430
No	63	24	87	72.41%
Drinking
Yes	20	13	33	60.61%	1.858	0.173
No	76	28	104	73.08%
Weight loss
Yes	38	15	53	71.70%	0.140	0.708
No	57	26	83	68.67%
Unknown	1	0	1	100%
Family history
Yes	12	8	20	60.00%	1.133	0.287
No	84	33	117	71.79%
Tumor location
Proximal gastric cancer	31	12	43	72.09%	1.971	0.373
Distal gastric cancer	57	28	85	67.06%
Total stomach	8	1	9	88.89%
Borrmann type
I/II	54	23	77	70.13%	0.005	0.944
III/IV	41	17	58	70.69%
Unknown	1	1	2	50%
Lauren type
Intestinal	45	24	69	65.22%	1.653	0.438
Diffuse	38	12	50	76.00%
Mixed	13	5	18	72.22%
Grade of differentiation
Poor/well	40	21	61	65.57%	0.913	0.339
Moderate/moderate-poor	52	19	71	73.24%
Unknown	4	1	5	80%
Pathological type
Signet ring cell carcinoma/mucinous adenocarcinoma	8	6	14	57.14%	0.355	0.207
Adenocarcinoma	88	35	123	71.54%
Tumor size (cm)
≥5 cm	66	23	89	74.15%	2.033	0.154
<5 cm	28	17	45	62.22%
Unknown	2	1	3	66.67%
T stage
T1/T2	2	5	7	28.57%	0.025	0.025
T3/T4	94	36	130	72.31%
N stage
N0	9	1	10	90.00%	0.281	0.141
N1/N2/N3	87	40	127	68.50%
M stage
M0	85	39	124	68.55%	0.343	0.191
M1	11	2	13	84.62%
TNM stage
I/II/III	85	39	124	68.55%	0.343	0.191
IV	11	2	13	84.62%
Nerve invasion
Positive	72	31	103	69.90%	0.006	0.940
Negative	24	10	34	70.59%
Vascular invasion
Positive	56	24	80	70.00%	<0.001	0.982
Negative	40	17	57	70.18%
AFP (ng/ml)
>8.1	6	2	8	75.00%	1.000	0.560
≤8.1	89	38	127	70.08%
Unknown	1	1	2	50.00%
CA19-9 (U/ml)
>37	36	10	46	78.26%	2.333	0.127
≤37	59	31	90	65.56%
Unknown	1	0	1	100.00%

^bStatistically significant ().